Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Rxo (RXO) over the last 4 years, with Q4 2025 value amounting to $75.0 million.

  • Rxo's Change in Accured Expenses fell 2647.06% to $75.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 million, marking a year-over-year decrease of 9829.06%. This contributed to the annual value of $2.0 million for FY2025, which is 9829.06% down from last year.
  • According to the latest figures from Q4 2025, Rxo's Change in Accured Expenses is $75.0 million, which was down 2647.06% from -$2.0 million recorded in Q3 2025.
  • Rxo's 5-year Change in Accured Expenses high stood at $102.0 million for Q4 2024, and its period low was -$60.0 million during Q2 2023.
  • Its 4-year average for Change in Accured Expenses is $5.1 million, with a median of $1.0 million in 2022.
  • In the last 5 years, Rxo's Change in Accured Expenses tumbled by 95714.29% in 2023 and then surged by 200000.0% in 2024.
  • Quarter analysis of 4 years shows Rxo's Change in Accured Expenses stood at -$17.0 million in 2022, then rose by 29.41% to -$12.0 million in 2023, then surged by 950.0% to $102.0 million in 2024, then fell by 26.47% to $75.0 million in 2025.
  • Its Change in Accured Expenses was $75.0 million in Q4 2025, compared to -$2.0 million in Q3 2025 and -$56.0 million in Q2 2025.